How can we help?
Alzheimer/Dementia
Studies
- The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
- Endocannabinoid signalling in Alzheimer’s disease
- A molecular link between the active component of marijuana and Alzheimer’s disease pathology
- Neuroprotective effect of CBD… on beta-amyloid-induced toxicity in PC12 cells
- The Potential Therapeutic Effects of THC on Alzheimer’s Disease
- The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
- CBD in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
- CBD: A promising drug for neurodegenerative disorders?
- Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
- The role of the endocannabinoid system in Alzheimer’s disease
- The role of phytochemicals in the treatment and prevention of dementia
- Cannabinoids for the treatment of dementia
- Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression inSHSY5YAPP+ Cells Through PPARγ Involvement
- Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
- Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia
- Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
- Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
- Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model
- CBD Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells
- In vivo Evidence for Therapeutic Properties of CBD for Alzheimer’s Disease
- Neurological aspects of medical use of CBD
- Amyloid-beta inhibits E-S Potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition
- Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids
- Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease
- Alzheimer’s disease; taking the edge off with cannabinoids?
- Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
- Cannabinoids and Parkinson’s disease
- Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease
- Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
- Cannabinoids for the treatment of dementia
- Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease
- CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease
- Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice
- Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
- Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
- Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
- Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation
- Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study
- Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer’s disease
- Synthetic cannabinoids in dementia with agitation: Case studies and literature review
- The influence of cannabinoids on generic traits of neurodegeneration
- The potential therapeutic effects of THC on Alzheimer’s disease
- The role of the endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease